Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HPRT1 | P00492 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.35 |
| ▸ | XIAP | P98170 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PRNP | P04156 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7754182 | 0.79 | KDM4E (0.37) | HSD17B10ALDH1A1TDP1TSHRRAB9A | |
| SCHEMBL9353954 | 0.77 | HTT (0.37) | CYP2A6MEN1KMT2AMAPK1HTT | |
| SCHEMBL3750917 | 0.74 | LMNA (0.57) | HSD17B10ALDH1A1TDP1TSHRHIF1A | |
| SCHEMBL7670367 | 0.72 | MAPT (0.40) | HSD17B10ALDH1A1CYP2A6TSHRNPC1 | |
| Water SCHEMBL27715056 | 0.69 | ALDH1A1 (0.41) | HSD17B10ALDH1A1TDP1CYP2A6TSHR | |
| SCHEMBL515944 | 0.69 | CYP3A4 (0.41) | HSD17B10ALDH1A1TDP1CYP2A6TSHR | |
| SCHEMBL10411212 | 0.67 | — | — | |
| SCHEMBL24477031 | 0.67 | KDM4E (0.44) | HSD17B10ALDH1A1NPC1RAB9AXIAP | |
| SCHEMBL1801464 | 0.67 | ALDH1A1 (0.52) | HSD17B10ALDH1A1TDP1CYP2A6TSHR | |
| SCHEMBL272930 | 0.67 | ALDH1A1 (0.42) | HSD17B10ALDH1A1TDP1CYP2A6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105473566-A | Oridonin analogs, compositions, and methods related thereto | UNIV TEXAS | 2016-04-06 | — | — | CN | claimed |
| EP-1919854-B1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBVIE INC (US) | 2013-09-18 | — | — | EP | claimed |
| US-8034941-B2 | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-11 | — | — | US | claimed |
| US-20090258856-A1 | IMIDAZOPYRIDAZINONE AND IMIDAZOPYRIDONE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-15 | — | — | US | claimed |
| US-7566707-B2 | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-28 | — | — | US | claimed |
| EP-1641799-B1 | IMIDAZO-PYRIDAZINONE DERIVATIVES AND IMIDAZO-PYRIDONE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2008-03-12 | — | — | EP | claimed |
| US-20050026921-A1 | New imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-03 | — | — | US | claimed |
| US-20030008829-A1 | Peptidyl heterocyclic ketones useful as tryptase inhibitors | COSTANZO MICHAEL J (US) | 2003-01-09 | — | — | US | claimed |
| EP-0833839-B1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMA CORP (US) | 2003-01-08 | — | — | EP | claimed |
| US-6323219-B1 | PRODRUGS AND PEPTIDES FOR ANTIINFLAMMATORY AGENTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-11-27 | — | — | US | claimed |
| WO-2000044733-A1 | PEPTIDYL HETEROCYCLIC KETONES USEFUL AS TRYPTASE INHIBITORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-08-03 | — | — | WO | claimed |
| CN-1241998-A | Synthesis of benzo (F) quinolinones | LILLY CO ELI (US) | 2000-01-19 | — | — | CN | claimed |
| EP-0969003-A2 | Process for the preparation of benzo[f]quinolinone derivatives and intermediates | ELI LILLY AND COMPANY (US) | 2000-01-05 | — | — | EP | claimed |
| CN-1192747-A | Peptidyl heterocyclic compounds for the treatment of thrombin-related diseases | ORTHO PHARMA CORP (US) | 1998-09-09 | — | — | CN | claimed |
| EP-0839807-A1 | Synthesis of benzo(f)quinolinones | ELI LILLY AND COMPANY (US) | 1998-05-06 | — | — | EP | claimed |
| EP-0833839-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-04-08 | — | — | EP | claimed |
| WO-1996040741-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040742-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATEDDISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040748-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | claimed |
| US-5523308-A | SERINE PROTEASES INHIBITORS; ORAL ANTICOAGULANTS; CHEMICAL INTERMEDIATES; DIPEPTIDES | ORTHO PHARMACEUTICAL CORPORATION | 1996-06-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258856-A1 | IMIDAZOPYRIDAZINONE AND IMIDAZOPYRIDONE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP4, DPP3, DPP7 | HSD17B10 1027/4885ALDH1A1 213/4885TDP1 727/4885 |
| US-20030008829-A1 | Peptidyl heterocyclic ketones useful as tryptase inhibitors | CMA1, TPSB2, TPSAB1 | HSD17B10 1036/4885ALDH1A1 1904/4885TDP1 3210/4885 |
| US-20050026921-A1 | New imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | HSD17B10 1093/4885ALDH1A1 239/4885TDP1 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.